Home
About
Overview
Sharing Data
ORCID
Help
History (19)
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Prevalence of RFC1-mediated spinocerebellar ataxia in a North American ataxia cohort.
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
See All 19 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
View in:
PubMed
subject areas
Acute Disease
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Chromosome Aberrations
Combined Modality Therapy
Cytarabine
Diarrhea
Dose-Response Relationship, Drug
Female
fms-Like Tyrosine Kinase 3
Hematologic Diseases
Humans
Kaplan-Meier Estimate
Leukemia, Myeloid
Male
Middle Aged
Mitoxantrone
Neoplasm Proteins
Neoplasms, Second Primary
Prognosis
Recurrence
Remission Induction
Retrospective Studies
Risk
Stem Cell Transplantation
Transplantation, Homologous
Young Adult
authors with profiles
Olatoyosi Odenike
Lucy Godley
Christopher Daugherty
Michael Thirman
Sandeep Gurbuxani
Dorothy A. Sipkins
Wendy Stock
Richard Larson
Dezheng Huo
Koen Van Besien